-
The "Regulations on the Administration of Medical Institutions" welcomes another major adjustment!
Time of Update: 2022-05-25
The specific revisions are as follows: Amend Article 9 of the Regulations on the Administration of Medical Institutions to read: “Where a unit or individual establishes a medical institution, and in accordance with the provisions of the State Council, it shall apply for the approval letter for setting up a medical institution, and shall be subject to examination by the health administrative department of the local people’s government at or above the county level.
-
Cefoperazone Sodium and Sulbactam Sodium for Erye Pharmaceutical Injection Passed Consistency Evaluation of Generic Drugs
Time of Update: 2022-05-25
Data source: Minet database On April 6, NMPA's official website showed that Suzhou Erye Pharmaceutical's cefoperazone sodium and sulbactam sodium for injection passed the consistency evaluation of generic drugs, making it the third company to pass the evaluation .
-
Saisheng Pharmaceutical's Small Molecule Conjugate Drug Application for Clinical Application
Time of Update: 2022-05-25
PEN-866 is a small molecule drug conjugate (SMDC) developed by Saison Pharmaceuticals and is currently conducting a Phase II basket trial for solid tumors in the United States .
-
The pharmaceutical manufacturing industry is on the brakes!
Time of Update: 2022-05-25
A few days ago, the National Bureau of Statistics released industrial economic operation data. From January to February 2022, the operating income of China's pharmaceutical manufacturing enterprises
-
AbbVie's JAK Inhibitor "Upatinib" Approved in China for the Third Indication
Time of Update: 2022-05-25
Article source: Medical Cube InfoOn April 6, the official website of the Food and Drug Administration showed that another marketing application for AbbVie’s upadatinib extended-release tablets was approved for the treatment of active patients with poor efficacy or intolerance to one or more DMARDs.
-
The first new drug for Parkinson's disease in more than ten years!
Time of Update: 2022-05-25
In March 2017, the FDA announced approval of safinamide tablets (trade name Xadago) as an add-on therapy for Parkinson's disease patients currently taking levodopa/carbidopa and experiencing "off" episodes .
-
The evaluation of basic medicines in tertiary hospitals has changed!
Time of Update: 2022-05-25
When the 2018 version of the tertiary hospital index assessment was issued, the "1+X" and "9-8-6" basic drug allocation requirements for basic drugs had not yet been introduced (it was only introduced in the document on shortage drug management in 2019), At that time, items (18) and (19) did not have extended indicators for the assessment of the number of varieties.
-
China's pharmaceutical and life sciences industry M&A transaction volume hits record high in 2021
Time of Update: 2022-05-25
The report predicts that China's aging population and the impact of the new crown epidemic will continue to increase market demand in the pharmaceutical and life science industries, and the long-term trend will remain positive .
-
Liver cancer treatment drugs and in-hospital market analysis
Time of Update: 2022-05-25
In October 2020, the National Medical Products Administration approved Roche's atezolizumab in combination with bevacizumab for the treatment of patients with unresectable hepatocellular carcinoma who have not received systemic therapy before .
-
Innovent's FGFR inhibitor approved for marketing
Time of Update: 2022-05-25
Article source: Medical Cube InfoAuthor: infoOn April 6, the NMPA approved the marketing application of Innovent Bio-Fibroblast Growth Factor Receptor (FGFR) 1/2/3 inhibitor pemigatinib for at least one prior systemic therapy , and adult patients with advanced, metastatic, or unresectable cholangiocarcinoma with confirmed FGFR2 fusions or rearrangements .
-
In order to adjust the development layout, domestic pharmaceutical companies are accelerating "slimming"
Time of Update: 2022-05-24
It is worth mentioning that on March 9, Ruizhi Pharmaceutical also issued an announcement on the sale of assets, saying that it planned to sell 100% equity of its wholly-owned subsidiary Kaihui Pharmaceutical (Shanghai) Co.
-
In the first quarter, over 90 domestic biopharmaceutical companies completed financing
Time of Update: 2022-05-24
Analysts said that in the first quarter of 2022, the total scale of investment and financing in the medical and health field was relatively stable, and the number of investment and financing events and the amount involved increased .
-
The CTLA-4, PD-1 track is crowded, and the development of the next generation of tumor immunotherapy is a new target for drug companies
Time of Update: 2022-05-24
As the track becomes more crowded, some pharmaceutical companies have announced the termination of the research and development of this variety of drugs.
Under the current fierce competition on the track, developing the next generation of tumor immunotherapy is becoming the goal of some pharmaceutical companies and researchers .
-
Kelun Pharmaceutical's 2021 net profit will increase by 33% year-on-year
Time of Update: 2022-05-24
On April 10, Kelun Pharmaceutical released the 2021 performance report: the operating income in 2021 will be about 17.
103 billion yuan, a year-on-year increase of 32.
103 billion yuan, a year-on-year increase of 32.
78 yuan, a year-on-year increase of 34.
-
HSK36273 for Haisco's innovative drug injection was approved for clinical trial
Time of Update: 2022-05-24
According to the "Pharmaceutical Administration Law of the People's Republic of China" and relevant regulations, after review, HSK36273 for injection accepted by the State Food and Drug Administration in January 2022 met the relevant requirements for drug registration, and was approved to carry out "systemic treatment for hemodialysis and intraoperative patients.
-
New drug for Parkinson's disease may soon be launched in China
Time of Update: 2022-05-24
In this context, the industry generally believes that with the background of a huge patient base and the deepening of global Lai Lihua, Parkinson's disease treatment drugs will have broader market prospects in the future, and more and more companies will enter the competition.
-
For adjuvant treatment of NSCLC!
Time of Update: 2022-05-24
On April 11, the CDE official website showed that BeiGene's tislelizumab + osperizumab combination therapy was approved for clinical use in adjuvant and neoadjuvant treatment of non-small cell lung cancer .
-
The original research meets the strong enemy!
Time of Update: 2022-05-24
In addition to Beite Pharmaceuticals, Sichuan Meida Kanghuakang Pharmaceuticals also submitted a supplementary application for the consistency evaluation of voriconazole for injection, but it is still under review and approval .
-
Suzhou Yilian Bio's YL201 clinical trial application obtained the US FDA's implied license
Time of Update: 2022-05-24
On April 9, 2022, YL201, an innovative drug independently developed by Suzhou Yilian Biopharmaceutical Co.
YL201 is an antibody-drug conjugate (ADC), and the target ADC is in the early clinical stage worldwide .
The toxin linker is an innovative structure.
-
Baiji Baiji, Nuocheng Jianhua, Hengrui and other pharmaceutical companies enter the tens of billions of BTK inhibitor market
Time of Update: 2022-05-24
According to relevant data analysis, the global market for BTK inhibitors is growing rapidly and is expected to reach US$11.
Take Nuocheng Jianhua's orelabrutinib as an example, which was approved in China on December 25, 2020 for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and Two indications for relapsed/refractory mantle cell lymphoma (MCL) .
